AzurRx BioPharma CEO James Sapirstein to Present at 2021 BIO Digital
08 juin 2021 07h00 HE
|
AzurRx BioPharma, Inc.
BOCA RATON, Fla., June 08, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
UPDATE - FMW Media, Inc.’s “New to The Street” TV Announces 6 Interviews Being Broadcast on NEWSMAX TV, Sunday, June 06, 2021, Hour Slot 10-11 AM ET
04 juin 2021 14h01 HE
|
FMW Media Works Corp
NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- FMW Media’s “New to The Street” TV broadcasting its national syndicated 1- hour show, Sunday, June 06, 2021 on NEWSMAX TV from 10-11AM ET. “New To The...
FMW Media, Inc.’s “New to The Street” TV Announces 6 Interviews Being Broadcast on NEWSMAX TV, Sunday, June 06, 2021, Hour Slot 10-11 AM ET
04 juin 2021 13h02 HE
|
FMW Media Works Corp
NEW YORK, June 04, 2021 (GLOBE NEWSWIRE) -- FMW Media’s “New to The Street” TV broadcasting its national syndicated 1- hour show, Sunday, May 16, 2021 on NEWSMAX TV from 10-11AM ET. “New To The...
FMW Media’s “New To The Street” Syndicated TV Show Features AzurRx BioPharma, Inc.
14 mai 2021 14h45 HE
|
FMW Media Works Corp
NEW YORK, May 14, 2021 (GLOBE NEWSWIRE) -- FMW Media Corp. announces that its “New To The Street” business TV show will feature AzurRx BioPharma, Inc. (NASDAQ: AZRX) in a 3-part TV series featured...
AzurRx BioPharma Announces Positive Interim Data in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency
13 mai 2021 07h00 HE
|
AzurRx BioPharma, Inc.
Data from first 18 patients indicate MS1819 and PERT combination led to clinically meaningful improvements in primary efficacy endpoint Full top-line data expected in Q2 2021 DELRAY BEACH, Fla., May...
AzurRx BioPharma to Present at the Emerging Growth Conference (May 12)
11 mai 2021 08h30 HE
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., May 11, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
AzurRx BioPharma to Present at Investor Summit Group’s Q2 Virtual Investor Summit (May 17)
11 mai 2021 07h30 HE
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., May 11, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of...
AzurRx BioPharma CEO Issues Letter to Shareholders
15 avr. 2021 07h30 HE
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., April 15, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development...
AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for Grade 1 Immune Checkpoint Inhibitor-Associated Colitis
13 avr. 2021 08h30 HE
|
AzurRx BioPharma, Inc.
DELRAY BEACH, Fla., April 13, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development...
AzurRx BioPharma Initiates Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
06 avr. 2021 07h00 HE
|
AzurRx BioPharma, Inc.
“RESERVOIR” trial to evaluate niclosamide’s ability to target SARS-CoV-2 in the GI tract Topline data expected in Q1 2022 DELRAY BEACH, Fla., April 06, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma,...